Last updated: September 8, 2026
CYRAMZA, Eli Lilly’s ramucirumab, is a mature oncology biologic with annual sales of approximately $1.1 billion. Its revenue base has remained resilient because it is approved across gastric cancer, non-small cell lung cancer, colorectal cancer, and hepatocellular carcinoma. The main commercial risks are competition from immunotherapies and newer targeted agents, declining use in later-line treatment, and eventual biosimilar entry after the U.S. biologic exclusivity period and relevant patent barriers expire.
What is CYRAMZA and how does it work?
CYRAMZA is a recombinant human IgG1 monoclonal antibody that binds vascular endothelial growth factor receptor 2, or VEGFR-2. By blocking VEGF ligand activation of VEGFR-2, ramucirumab inhibits tumor angiogenesis.
| Attribute |
CYRAMZA |
| Active ingredient |
Ramucirumab |
| Manufacturer |
Eli Lilly and Company |
| Product type |
Recombinant monoclonal antibody |
| FDA application |
BLA 125477 |
| Route |
Intravenous infusion |
| Initial U.S. approval |
April 21, 2014 |
| Therapeutic class |
Anti-angiogenic oncology biologic |
| Primary mechanism |
VEGFR-2 antagonism |
| U.S. reference-product exclusivity |
Generally 12 years from first licensure, subject to statutory calculations |
| Orange Book status |
Not listed as a conventional small-molecule drug |
| Biologic reference |
Listed through FDA biologics and Purple Book frameworks |
CYRAMZA is administered intravenously, which limits convenience compared with oral oncology products but supports use in infusion-center treatment protocols.
Which indications drive CYRAMZA sales?
CYRAMZA has four major U.S. indications. Its commercial value is distributed across several tumor types rather than concentrated in a single approved use.
| Indication |
Regimen or setting |
FDA milestone |
Commercial role |
| Gastric or gastroesophageal junction adenocarcinoma |
Monotherapy or with paclitaxel after prior fluoropyrimidine or platinum therapy |
2014 |
Original anchor indication |
| Metastatic non-small cell lung cancer |
With docetaxel after platinum-based chemotherapy |
2014 |
Important but pressured by immunotherapy |
| Metastatic colorectal cancer |
With FOLFIRI after prior bevacizumab-, oxaliplatin-, and fluoropyrimidine-containing therapy |
2015 |
Later-line niche |
| Hepatocellular carcinoma |
Monotherapy after sorafenib in patients with AFP of at least 400 ng/mL |
2019 |
Biomarker-defined, narrower opportunity |
The hepatocellular carcinoma indication is commercially differentiated because it uses alpha-fetoprotein, or AFP, to identify patients with a greater likelihood of benefit. That restriction also limits the eligible population.
The gastric cancer indication remains strategically important because CYRAMZA has a defined role after first-line chemotherapy. The lung cancer indication has faced greater pressure from immune checkpoint inhibitors, which have moved into earlier lines of treatment.
How has CYRAMZA revenue developed?
CYRAMZA has generated a stable revenue stream rather than the rapid growth associated with newer oncology products. Eli Lilly reported approximately $1.1 billion in CYRAMZA revenue in 2023, with sales broadly stable compared with 2022. The product accounted for roughly 3% of Lilly’s 2023 revenue, based on total company revenue of approximately $34.1 billion.[1]
| Fiscal year |
Approximate CYRAMZA revenue |
Financial interpretation |
| 2019 |
$0.9 billion |
Expansion supported by established solid-tumor use |
| 2020 |
$0.95 billion |
Resilient despite pandemic-related treatment disruption |
| 2021 |
$1.0 billion |
Broad indication base supported demand |
| 2022 |
$1.05 billion |
Mature growth profile |
| 2023 |
$1.06 billion |
Stable sales, limited unit expansion |
The trajectory shows three phases:
- Initial expansion after the 2014 launch and subsequent colorectal cancer approval.
- Stabilization as the product reached broad commercial maturity.
- Increasing competitive pressure as immunotherapies and newer targeted medicines displaced chemotherapy-based treatment sequences.
CYRAMZA remains financially relevant to Lilly, but its strategic importance is lower than that of newer growth products such as MOUNJARO, Zepbound, Verzenio, and Taltz. Its predictable revenue can support the oncology portfolio, but it is unlikely to be a major driver of Lilly’s consolidated growth.
What are CYRAMZA’s main market growth drivers?
CYRAMZA’s market position is supported by several factors.
Multiple tumor indications
The product is approved in four major cancer settings. That diversification reduces dependence on one cancer type or treatment guideline.
Combination use
CYRAMZA is used with paclitaxel, docetaxel, and FOLFIRI in approved settings. Combination regimens can preserve utilization when monotherapy demand weakens.
Later-line treatment need
Patients who progress after first-line therapy continue to require additional treatment options. CYRAMZA benefits from this continuing need, particularly in gastric cancer and colorectal cancer.
Biomarker-defined liver cancer use
The AFP threshold in hepatocellular carcinoma identifies a higher-risk population that may have limited alternatives after sorafenib. The indication provides differentiation even though the addressable market is narrower.
Established reimbursement and clinical familiarity
CYRAMZA has been marketed for a decade in the United States. Oncologists, infusion centers, and payers have established treatment pathways, reducing adoption friction.
What competitive drugs pressure CYRAMZA?
CYRAMZA competes with both direct anti-angiogenic agents and broader oncology therapies that occupy the same treatment lines.
| Disease area |
Major competing therapies |
Competitive effect |
| Gastric cancer |
Paclitaxel, pembrolizumab, nivolumab, trastuzumab deruxtecan, trifluridine/tipiracil |
Limits later-line market and shifts treatment toward biomarker-selected therapies |
| Non-small cell lung cancer |
Pembrolizumab, nivolumab, atezolizumab, docetaxel, pemetrexed, targeted kinase inhibitors |
Moves CYRAMZA later in the treatment sequence |
| Colorectal cancer |
Bevacizumab, aflibercept, ziv-aflibercept, regorafenib, trifluridine/tipiracil, cetuximab, panitumumab |
Creates substantial anti-angiogenic and targeted competition |
| Hepatocellular carcinoma |
Atezolizumab plus bevacizumab, durvalumab plus tremelimumab, cabozantinib, regorafenib, nivolumab, pembrolizumab |
Reduces the post-sorafenib treatment pool |
The most significant commercial threat is treatment migration into earlier-line immunotherapy combinations. CYRAMZA is generally used after prior therapy, while checkpoint inhibitors and molecularly targeted agents have gained earlier access in several tumor types.
CYRAMZA also competes with Roche’s Avastin, or bevacizumab, in colorectal cancer and other solid tumors. Avastin has biosimilar competition, which can create pricing pressure across anti-angiogenic treatment categories even where CYRAMZA does not face direct substitution.
When does CYRAMZA lose exclusivity?
CYRAMZA’s U.S. regulatory exclusivity and patent protection have different timelines.
Biologic exclusivity
CYRAMZA received its first U.S. approval on April 21, 2014. Under the Biologics Price Competition and Innovation Act, a biosimilar generally cannot be approved until 12 years after the reference product’s first licensure, subject to statutory treatment of the application and product history.[2]
The principal U.S. reference-product exclusivity period therefore points to April 2026 as the earliest broad approval window for a competing biosimilar, although actual market entry depends on patent disputes, settlement agreements, manufacturing readiness, and FDA review.
Patent exclusivity
Patent expiration is more complex than the 12-year biologic exclusivity date. Relevant protection may include:
- Antibody composition claims.
- Sequence or epitope claims.
- Pharmaceutical composition claims.
- Manufacturing and purification claims.
- Dosing and method-of-treatment claims.
- Patents covering specific cancer indications or patient populations.
Public patent records identify ramucirumab-related U.S. patents with expiration dates extending beyond the initial regulatory exclusivity period. The practical biosimilar entry date will depend on which claims remain enforceable and whether Lilly obtains patent-term adjustment, pediatric exclusivity, or litigation-related relief.[3]
What is the Orange Book status of CYRAMZA?
CYRAMZA is a biologic, not a conventional small-molecule drug. It is therefore not evaluated through the standard Orange Book framework used for abbreviated new drug applications.
A biosimilar applicant would use the FDA’s abbreviated biologics pathway under section 351(k) of the Public Health Service Act. The relevant competitive process includes:
- Reference-product exclusivity.
- FDA Purple Book information.
- Patent information exchanged under the BPCIA.
- Patent litigation under 35 U.S.C. § 271(e)(2).
- Commercial-launch timing and possible settlement restrictions.
The absence of a conventional Orange Book listing does not mean CYRAMZA lacks patent protection. It means the legal and regulatory pathway differs from that for drugs such as small-molecule kinase inhibitors.
Are there CYRAMZA biosimilar or Paragraph IV challenges?
No major publicly established CYRAMZA biosimilar launch or widely reported BPCIA litigation had materially changed the product’s U.S. market position through the latest publicly available information used for this analysis.
Paragraph IV certification is a Hatch-Waxman concept that applies principally to abbreviated new drug applications. CYRAMZA competitors would generally pursue the biosimilar pathway rather than a conventional Paragraph IV generic challenge.
The absence of an approved biosimilar does not eliminate future risk. A competitive applicant could challenge composition, formulation, manufacturing, or method-of-use patents before commercial launch. The most likely sequence is:
- Biosimilar development and analytical comparability work.
- A 351(k) filing after statutory reference-product exclusivity.
- BPCIA patent-information exchange.
- Patent litigation or negotiated settlement.
- FDA approval followed by a delayed or immediate launch depending on the agreement.
How strong is the CYRAMZA patent estate?
CYRAMZA has a moderate commercial patent position.
Its strength is supported by the complexity of a monoclonal antibody product. Biosimilar developers must demonstrate analytical similarity, clinical comparability, manufacturing consistency, and regulatory interchangeability if they seek interchangeable status. These requirements create higher development costs than for a conventional generic.
The estate is weaker than a patent portfolio built around a new chemical entity with numerous independent composition patents. CYRAMZA’s core molecule has been commercially known for many years, and the product’s mature clinical profile gives competitors time to develop alternative manufacturing processes.
The most defensible protection is likely to involve:
- Core antibody claims that remain unexpired.
- Specific formulation or stability claims.
- Manufacturing claims that are difficult to design around.
- Dosing claims tied to defined cancer populations.
Method-of-use patents are less likely to block an entire biosimilar market if competitors can pursue non-infringing labels or omit protected indications. Formulation and manufacturing patents can create more practical barriers because they may affect the economics and regulatory package of the biosimilar itself.
What manufacturing and intellectual-property barriers affect CYRAMZA competition?
Ramucirumab is produced through mammalian-cell culture and requires control of glycosylation, aggregation, potency, impurities, and stability. A biosimilar manufacturer must match clinically relevant quality attributes without using Lilly’s proprietary cell line or process.
Key barriers include:
- Scale-up of antibody production.
- Consistency across commercial batches.
- Demonstration of comparable pharmacokinetics.
- Validation of aseptic filling and infusion stability.
- Control of immunogenicity risk.
- Development of a commercially competitive cost structure.
These barriers favor large biologics manufacturers and contract development and manufacturing organizations. Potential competitors are more likely to include established companies such as Samsung Bioepis, Amgen, Celltrion, Sandoz, Biocon Biologics, Fresenius Kabi, or other large-scale biologics developers than conventional generic-drug companies.
What patent litigation and settlement risks affect CYRAMZA?
The principal litigation risk is future BPCIA litigation involving a biosimilar applicant. Relevant disputes could address:
- Whether a patent claims ramucirumab itself.
- Whether the biosimilar process infringes a manufacturing claim.
- Whether a proposed label induces infringement of a protected indication.
- Whether a formulation patent covers the applicant’s product.
- Whether Lilly properly listed or disclosed relevant patent rights.
- Whether an injunction would delay commercial launch.
A settlement could allow launch before the latest asserted patent expiration while preserving Lilly’s commercial control until an agreed date. The absence of a public settlement does not establish that no confidential licensing or patent discussions exist.
What licensing deals are connected to CYRAMZA?
CYRAMZA originated from ImClone Systems and became part of Lilly’s portfolio through Lilly’s acquisition of ImClone in 2008. The acquisition transferred rights to ramucirumab and other oncology assets to Lilly.[4]
No major current co-commercialization arrangement is central to CYRAMZA’s global market position. Lilly remains the primary commercial owner and marketer. Regional distribution or commercialization arrangements may exist in individual markets, but they do not appear to define the product’s principal value model.
How does CYRAMZA compare with Avastin and newer immunotherapies?
| Factor |
CYRAMZA |
Avastin |
Immunotherapy products |
| Target |
VEGFR-2 |
VEGF-A |
PD-1, PD-L1, CTLA-4 or related immune pathways |
| Product age |
Launched 2014 |
Launched 2004 |
Varies by product |
| Administration |
IV infusion |
IV infusion |
Usually IV infusion |
| Biosimilar pressure |
Emerging future risk |
Established and significant |
Increasing for older checkpoint inhibitors |
| Use pattern |
Mostly later-line and combination therapy |
Broad solid-tumor use |
Increasingly earlier-line |
| Commercial outlook |
Stable, mature |
Large but price pressured |
Growth concentrated in selected indications |
CYRAMZA’s differentiation is strongest where it has a defined later-line role and where clinicians need an anti-angiogenic option after prior treatment. Its position is weaker where immunotherapy has become the preferred first-line or second-line standard.
What generic launch scenarios exist for CYRAMZA?
Three scenarios are commercially plausible.
Early biosimilar entry after exclusivity
A biosimilar could enter soon after the statutory reference-product exclusivity period if Lilly’s remaining patents do not support a launch injunction. This scenario would create rapid payer-led price pressure.
Delayed entry through patent settlement
Lilly could settle with one or more developers, permitting launch on a negotiated date before the latest patent expiration. A staggered launch could produce limited initial competition followed by multiple entrants.
Extended protection through litigation
If key composition, formulation, or manufacturing claims survive, commercial biosimilar entry could be delayed beyond 2026. This would preserve revenue but would not prevent clinical substitution by competing therapies.
The most likely long-term outcome is gradual erosion rather than an immediate collapse. Hospital and oncology purchasing organizations may adopt biosimilars quickly once multiple suppliers are available, but CYRAMZA’s broad indication footprint and established physician use could support residual branded demand.
What is CYRAMZA’s geographic market exposure?
The United States is the most important market for Lilly’s oncology revenue, but CYRAMZA is marketed internationally. Pricing, patent terms, biosimilar approval standards, and reimbursement differ by region.
Europe may face earlier or more intense biosimilar pressure because biosimilar uptake is established in hospital oncology markets. Japan and other regulated markets may present separate approval and reimbursement timelines. Emerging markets can expand patient access but generally contribute lower revenue per treatment because of price controls, tendering, and reimbursement limits.
The commercial effect of biosimilar entry will therefore vary:
- United States: Litigation and contracting will determine timing and price erosion.
- Europe: Tendering and hospital purchasing can accelerate substitution.
- Japan: Regulatory review and reimbursement policy will influence uptake.
- Emerging markets: Volume growth may coexist with low net pricing.
Key Takeaways
- CYRAMZA is a mature anti-VEGFR-2 oncology biologic with approximately $1.1 billion in annual sales.
- Eli Lilly’s 2023 CYRAMZA revenue was broadly stable, making the product a durable but low-growth asset.
- Gastric cancer, lung cancer, colorectal cancer, and AFP-selected hepatocellular carcinoma diversify demand.
- Immunotherapies and newer targeted agents are moving CYRAMZA into later treatment lines.
- U.S. biologic exclusivity points to an earliest broad biosimilar approval window around April 2026.
- The product is not governed by the conventional Orange Book generic pathway.
- Future competition will depend on BPCIA litigation, composition and process patents, formulation claims, and settlement terms.
- CYRAMZA’s manufacturing complexity raises biosimilar barriers, but its mature market and large revenue base make it an attractive target for major biologics companies.
- Revenue erosion is likely to be gradual unless multiple biosimilars launch at closely competing prices.
FAQs About CYRAMZA Market and Patent Risk
Is CYRAMZA a biologic or a generic drug?
CYRAMZA is a biologic monoclonal antibody. A competitor would generally require FDA approval as a biosimilar under the 351(k) pathway rather than as a conventional generic under an abbreviated new drug application.
Does CYRAMZA have interchangeable biosimilar competition?
No interchangeable CYRAMZA biosimilar had materially entered the U.S. market in the publicly available information used for this analysis. Interchangeability would require additional FDA findings beyond biosimilarity.
Why is CYRAMZA still used despite competition from immunotherapy?
CYRAMZA remains relevant in later-line treatment, combination regimens, gastric cancer, colorectal cancer, and biomarker-selected hepatocellular carcinoma where clinicians need additional treatment options after prior therapy.
Could CYRAMZA sales fall sharply after the first biosimilar launch?
A sharp decline is possible if payers favor the biosimilar and several competitors launch close together. A gradual decline is more likely if entry is staggered and Lilly preserves physician and payer preference through contracting.
Is CYRAMZA strategically important to Eli Lilly?
CYRAMZA is financially meaningful but not a primary growth engine. Its main strategic value is its stable oncology revenue, established treatment footprint, and contribution to Lilly’s mature-product portfolio.
References
- Eli Lilly and Company. (2024). 2023 annual report. https://investor.lilly.com/financial-information/annual-reports
- U.S. Food and Drug Administration. (2023). Implementation of the Biologics Price Competition and Innovation Act of 2009. https://www.fda.gov/drugs/guidance-compliance-regulatory-information
- United States Patent and Trademark Office. (2024). Patent term adjustment and patent search resources. https://www.uspto.gov/patents
- Eli Lilly and Company. (2008). Lilly completes acquisition of ImClone Systems. https://investor.lilly.com/news-releases/default.aspx
- U.S. Food and Drug Administration. (2024). CYRAMZA prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/
